Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

GlobeNewswire May 10, 2022

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

GlobeNewswire April 25, 2022

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 16, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

GlobeNewswire March 11, 2022

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

GlobeNewswire March 8, 2022

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

GlobeNewswire March 3, 2022

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

GlobeNewswire March 2, 2022

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

GlobeNewswire February 24, 2022

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

GlobeNewswire February 17, 2022

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

GlobeNewswire February 7, 2022

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

GlobeNewswire February 3, 2022

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

GlobeNewswire January 28, 2022

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

GlobeNewswire January 10, 2022

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

GlobeNewswire January 4, 2022

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

GlobeNewswire December 6, 2021

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 15, 2021

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

GlobeNewswire November 9, 2021

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

GlobeNewswire October 25, 2021

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

GlobeNewswire September 30, 2021

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 17, 2021